BofA lowered the firm’s price target on Janux Therapeutics (JANX) to $24 from $29 and keeps a Buy rating on the shares. The firm increased its view of peak penetration for PSMA-targeting TCEs slightly to reflect the potential for improved safety, but continues to see JANX007 as “a lead asset,” the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JANX:
- Janux Therapeutics Adjusts Board Class Structure for Director
- Janux Therapeutics price target lowered to $28 from $50 at JonesResearch
- Janux Therapeutics announces discontinuation of JANX008 clinical development
- Janux’s JANX011 First‑in‑Human Study: Early Safety Readout Could Shape Autoimmune Upside
- Advancing PSMA Franchise and Validating TRACTr Platform Underpin Buy Rating on Janux Therapeutics